{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:02:37Z","timestamp":1784358157836,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81770165"],"award-info":[{"award-number":["No. 81770165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the SciTech Funding by CSPFTZ Lingang Special Area Marine Biomedical Innovation Platform"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12377-7","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:07:02Z","timestamp":1784354822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Increased MYB alternative promoter usage induces daunorubicin resistance in human leukemia cells via ABCA2 upregulation"],"prefix":"10.1007","volume":"53","author":[{"given":"Huiying","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8618-3570","authenticated-orcid":false,"given":"Bingshe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"12377_CR1","doi-asserted-by":"publisher","unstructured":"Lemma RB, Fuglerud BM, Frampton J, Gabrielsen OS (2024) MYB: a key transcription factor in the hematopoietic system subject to many levels of control, Transcription factors in blood cell development 3\u201329. https:\/\/doi.org\/10.1007\/978-3-031-62731-6_1","DOI":"10.1007\/978-3-031-62731-6_1"},{"key":"12377_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.gene.2018.04.065","volume":"665","author":"X Wang","year":"2018","unstructured":"Wang X, Angelis N, Thein SL (2018) MYB\u2013A regulatory factor in hematopoiesis. Gene 665:6\u201317. https:\/\/doi.org\/10.1016\/j.gene.2018.04.065","journal-title":"Gene"},{"key":"12377_CR3","doi-asserted-by":"publisher","unstructured":"Clarke ML, Gabrielsen OS, Frampton J (2024) MYB as a critical transcription factor and potential therapeutic target in AML, Transcription factors in blood cell development 341\u2013358. https:\/\/doi.org\/10.1007\/978-3-031-62731-6_15","DOI":"10.1007\/978-3-031-62731-6_15"},{"key":"12377_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.20517\/cdr.2023.158","volume":"7","author":"B Biersack","year":"2024","unstructured":"Biersack B, H\u00f6pfner M (2024) Emerging role of MYB transcription factors in cancer drug resistance. Cancer Drug Resist 7:15. https:\/\/doi.org\/10.20517\/cdr.2023.158","journal-title":"Cancer Drug Resist"},{"key":"12377_CR5","doi-asserted-by":"publisher","first-page":"106763","DOI":"10.1016\/j.oraloncology.2024.106763","volume":"151","author":"J Huang","year":"2024","unstructured":"Huang J, Fehr A, J\u00e4wert F, Nilsson JA, Morris LG, Stenman G, Andersson MK (2024) MYB alternative promoter activity is increased in adenoid cystic carcinoma metastases and is associated with a specific gene expression signature. Oral Oncol 151:106763. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106763","journal-title":"Oral Oncol"},{"key":"12377_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cancers12010045","volume":"12","author":"CA Frerich","year":"2020","unstructured":"Frerich CA, Sedam HN, Kang H, Mitani Y, El-Naggar AK, Ness SA (2020) N-Terminal Truncated Myb with New Transcriptional Activity Produced Through Use of an Alternative MYB Promoter in Salivary Gland Adenoid Cystic Carcinoma. Cancers 12:45. https:\/\/doi.org\/10.3390\/cancers12010045","journal-title":"Cancers"},{"key":"12377_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/gcc.23151","volume":"62","author":"A Fehr","year":"2023","unstructured":"Fehr A, Arvidsson G, Nordlund J, L\u00f6nnerholm G, Stenman G, Andersson MK (2023) Increased MYB alternative promoter usage is associated with relapse in acute lymphoblastic leukemia. Genes Chromosom Cancer 62:597\u2013606. https:\/\/doi.org\/10.1002\/gcc.23151","journal-title":"Genes Chromosom Cancer"},{"key":"12377_CR8","doi-asserted-by":"publisher","unstructured":"Hulst MB, Zhang L, van der Heul HU, Du C, Elsayed SS, Koroleva A, Grocholski T, Wander DP, Mets\u00e4-Ketel\u00e4 M, Neefjes JJ (2024) Metabolic engineering of Streptomyces peucetius for biosynthesis of N, N-dimethylated anthracyclines, Frontiers in bioengineering and biotechnology 12:1363803. https:\/\/doi.org\/10.3389\/fbioe.2024.1363803","DOI":"10.3389\/fbioe.2024.1363803"},{"key":"12377_CR9","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.3390\/microorganisms12122639","volume":"12","author":"B Pudhuvai","year":"2024","unstructured":"Pudhuvai B, Bene\u0161 K, \u010curn V, Bohata A, Lencova J, Vrzalova R, Barta J, Matha V (2024) The daunomycin: biosynthesis, actions, and the search for new solutions to enhance production. Microorganisms 12:2639. https:\/\/doi.org\/10.3390\/microorganisms12122639","journal-title":"Microorganisms"},{"key":"12377_CR10","doi-asserted-by":"publisher","unstructured":"Mattioli R, Ilari A, Colotti B, Mosca L, Fazi F, Colotti G (2023) Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming. Molecular aspects of medicine 93:101205. https:\/\/doi.org\/10.1016\/j.mam.2023.101205","DOI":"10.1016\/j.mam.2023.101205"},{"key":"12377_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3324\/haematol.2021.280161","volume":"107","author":"JM Rowe","year":"2022","unstructured":"Rowe JM (2022) The 7\u2009+\u20093 regimen in acute myeloid leukemia. Haematologica 107:3. https:\/\/doi.org\/10.3324\/haematol.2021.280161","journal-title":"Haematologica"},{"key":"12377_CR12","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3324\/haematol.2022.281045","volume":"107","author":"A Tefferi","year":"2022","unstructured":"Tefferi A, Gangat N, Shah M, Alkhateeb H, Patnaik MS, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC (2022) Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience. Haematologica 107:2474. https:\/\/doi.org\/10.3324\/haematol.2022.281045","journal-title":"Haematologica"},{"key":"12377_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/cancers16040723","volume":"16","author":"H Hayashi","year":"2024","unstructured":"Hayashi H, Makimoto A, Yuza Y (2024) Treatment of pediatric acute lymphoblastic leukemia: a historical perspective. Cancers 16:723. https:\/\/doi.org\/10.3390\/cancers16040723","journal-title":"Cancers"},{"key":"12377_CR14","doi-asserted-by":"publisher","unstructured":"Zhang J, Gu Y, Chen B (2019) Mechanisms of drug resistance in acute myeloid leukemia. OncoTargets therapy 12:1937\u20131945. https:\/\/doi.org\/10.2147\/OTT.S191621","DOI":"10.2147\/OTT.S191621"},{"key":"12377_CR15","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/humu.24418","volume":"43","author":"M Dean","year":"2022","unstructured":"Dean M, Moitra K, Allikmets R (2022) The human ATP-binding cassette (ABC) transporter superfamily. Hum Mutat 43:1162\u20131182. https:\/\/doi.org\/10.1002\/humu.24418","journal-title":"Hum Mutat"},{"key":"12377_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.trecan.2023.09.013","volume":"10","author":"L Duvivier","year":"2024","unstructured":"Duvivier L, Gerard L, Diaz A, Gillet J-P (2024) Linking ABC transporters to the hallmarks of cancer. Trends Cancer 10:124\u2013134. https:\/\/doi.org\/10.1016\/j.trecan.2023.09.013","journal-title":"Trends Cancer"},{"key":"12377_CR17","doi-asserted-by":"publisher","unstructured":"Marques AVL, Ruginsk BE, de Oliveira Prado L, de Lima DE, Daniel IW, Moure VR, Valdameri G (2025) The association of ABC proteins with multidrug resistance in cancer. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1872:119878. https:\/\/doi.org\/10.1016\/j.bbamcr.2024.119878","DOI":"10.1016\/j.bbamcr.2024.119878"},{"key":"12377_CR18","doi-asserted-by":"publisher","unstructured":"Zhu X, Zhuo Y, Wu S, Chen Y, Ye J, Deng Y, Feng Y, Liu R, Cai S, Zou Z (2021) Corrigendum: TFEB promotes prostate cancer progression via regulating ABCA2-dependent lysosomal biogenesis. Frontiers in Oncology 11:750277. https:\/\/doi.org\/10.3389\/fonc.2021.632524","DOI":"10.3389\/fonc.2021.632524"},{"key":"12377_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00280-023-04584-x","volume":"92","author":"Y Shibata","year":"2023","unstructured":"Shibata Y, Matsumoto N, Murase R, Kubota Y, Ishida H, Shimada K, Fujita K-i (2023) A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer. Cancer Chemother Pharmacol 92:465\u2013474. https:\/\/doi.org\/10.1007\/s00280-023-04584-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"12377_CR20","doi-asserted-by":"publisher","first-page":"115930","DOI":"10.1016\/j.biopha.2023.115930","volume":"170","author":"E Cerovska","year":"2024","unstructured":"Cerovska E, Salek C, Kundrat D, Sestakova S, Pesek A, Brozinova I, Belickova M, Remesova H (2024) ABC transporters are predictors of treatment failure in acute myeloid leukaemia. Biomed Pharmacother 170:115930. https:\/\/doi.org\/10.1016\/j.biopha.2023.115930","journal-title":"Biomed Pharmacother"},{"key":"12377_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3324\/haematol.2010.031823","volume":"96","author":"C Marzac","year":"2011","unstructured":"Marzac C, Garrido E, Tang R, Fava F, Hirsch P, De Benedictis C, Corre E, Lapusan S, Lallemand J-Y, Marie J-P (2011) ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients. Haematologica 96:1293. https:\/\/doi.org\/10.3324\/haematol.2010.031823","journal-title":"Haematologica"},{"key":"12377_CR22","doi-asserted-by":"publisher","unstructured":"Wang Y, Wang X, Li M, Song H, Liu C, Shi M, Tao X, Shen S, Li X, Fang H (2026) Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells. Leukemia 40:562\u2013576. https:\/\/doi.org\/10.1038\/s41375-026-02862-0","DOI":"10.1038\/s41375-026-02862-0"},{"key":"12377_CR23","doi-asserted-by":"publisher","unstructured":"Mitra P (2018) Transcription regulation of MYB: a potential and novel therapeutic target in cancer. Annals of translational medicine 6:443. https:\/\/doi.org\/10.21037\/atm.2018.09.62","DOI":"10.21037\/atm.2018.09.62"},{"key":"12377_CR24","doi-asserted-by":"publisher","first-page":"1126354","DOI":"10.3389\/fonc.2023.1126354","volume":"13","author":"P Tejera Nevado","year":"2023","unstructured":"Tejera Nevado P, Te\u0161an Tomi\u0107 T, Atefyekta A, Fehr A, Stenman G, Andersson MK (2023) Synthetic oleanane triterpenoids suppress MYB oncogene activity and sensitize T-cell acute lymphoblastic leukemia cells to chemotherapy. Front Oncol 13:1126354. https:\/\/doi.org\/10.3389\/fonc.2023.1126354","journal-title":"Front Oncol"},{"key":"12377_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10555-023-10153-8","volume":"43","author":"S Anand","year":"2024","unstructured":"Anand S, Vikramdeo KS, Sudan SK, Sharma A, Acharya S, Khan MA, Singh S, Singh AP (2024) From modulation of cellular plasticity to potentiation of therapeutic resistance: new and emerging roles of MYB transcription factors in human malignancies. Cancer Metastasis Rev 43:409\u2013421. https:\/\/doi.org\/10.1007\/s10555-023-10153-8","journal-title":"Cancer Metastasis Rev"},{"key":"12377_CR26","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1182\/blood.v98.4.913","volume":"98","author":"G Laurent","year":"2001","unstructured":"Laurent G, Jaffr\u00e9zou J-P (2001) Signaling pathways activated by daunorubicin, Blood. J Am Soc Hematol 98:913\u2013924. https:\/\/doi.org\/10.1182\/blood.v98.4.913","journal-title":"J Am Soc Hematol"},{"key":"12377_CR27","doi-asserted-by":"publisher","first-page":"20508","DOI":"10.1038\/srep20508","volume":"6","author":"E Andreev","year":"2016","unstructured":"Andreev E, Brosseau N, Carmona E, Mes-Masson A-M, Ramotar D (2016) The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin. Sci Rep 6:20508. https:\/\/doi.org\/10.1038\/srep20508","journal-title":"Sci Rep"},{"key":"12377_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.20517\/cdr.2019.117","volume":"3","author":"TS Elton","year":"2020","unstructured":"Elton TS, Ozer HG, Yalowich JC (2020) Effects of DNA topoisomerase II\u03b1 splice variants on acquired drug resistance. Cancer Drug Resist 3:161. https:\/\/doi.org\/10.20517\/cdr.2019.117","journal-title":"Cancer Drug Resist"},{"key":"12377_CR29","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3390\/cells13090740","volume":"13","author":"M Villa","year":"2024","unstructured":"Villa M, Wu J, Hansen S, Pahnke J (2024) Emerging role of ABC transporters in glia cells in health and diseases of the central nervous system. Cells 13:740. https:\/\/doi.org\/10.3390\/cells13090740","journal-title":"Cells"},{"key":"12377_CR30","doi-asserted-by":"publisher","unstructured":"Aberuyi N, Rahgozar S, Khosravi Dehaghi Z, Moafi A, Masotti A, Paolini A (2017) The translational expression of ABCA2 and ABCA3 is a strong prognostic biomarker for multidrug resistance in pediatric acute lymphoblastic leukemia. OncoTargets therapy 10:3373\u20133380. https:\/\/doi.org\/10.2147\/OTT.S140488","DOI":"10.2147\/OTT.S140488"},{"key":"12377_CR31","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.7150\/ijbs.91832","volume":"20","author":"Y Huang","year":"2024","unstructured":"Huang Y, Zhang R, Lyu H, Xiao S, Guo D, Chen X-Z, Zhou C, Tang J (2024) LncRNAs as nodes for the cross-talk between autophagy and Wnt signaling in pancreatic cancer drug resistance. Int J Biol Sci 20:2698. https:\/\/doi.org\/10.7150\/ijbs.91832","journal-title":"Int J Biol Sci"},{"key":"12377_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/cancers15020428","volume":"15","author":"KJ Zi\u0119tara","year":"2023","unstructured":"Zi\u0119tara KJ, Lejman J, Wojciechowska K, Lejman M (2023) The importance of selected dysregulated microRNAs in diagnosis and prognosis of childhood B-cell precursor acute lymphoblastic leukemia. Cancers 15:428. https:\/\/doi.org\/10.3390\/cancers15020428","journal-title":"Cancers"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12377-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12377-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12377-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:07:04Z","timestamp":1784354824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12377-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12377"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12377-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1198"}}